Sofosbuvir & Velpatasvir

Myhep All

Indication:

WHAT DO YOU MEAN BY MYHEP ALL VELPATASVIR 100 MG & SOFOSBUVIR 400 MG TABLETS ?

MyHep All medication is a combination of sofosbuvir and velpatasvir. This drug work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover

WHAT ARE THE USES OF MYHEP ALL TABLETS ?
MyLan Pharmaceutical Sofosbuvir and Velpatasvir is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). SOFOSBUVIR VELPATASVIR COMMON SIDE EFFECTS : Common MyHep All side effects may include: headache; tired feeling; nausea, diarrhea; or sleep problems (insomnia). Call your doctor at once if you have: slow heartbeats; weak or shallow breathing; or low red blood cells-pale skin, weakness, rapid heart rate, trouble concentrating. If you also take amiodarone: Seek medical help right away if you feel weak, tired, or light-headed, or if you have chest pain, shortness of breath, confusion, or memory problems. This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects.


Brand name: Myhep All

Active Ingeridents: Sofosbuvir-400Mg-Velpatasvir-100Mg

Company Name: Mylan

Package: 28 tabs/bottle

Strength : 400 MG & 100 MG

Sofosbuvir Mechanism of action:

Sofosbuvir Plus Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir plus velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

Dosage and Administration:

Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg plus velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.

  • Renal Impairment: For patients with mild to moderate renal impairment, no dosage adjustment of sofosbuvir-velpatasvir is recommended. There are insufficient data regarding the safety and efficacy of sofosbuvir-velpatasvir in patients with severe renal impairment (eGFR less than 30 ml/min/1.73m2) or end-stage renal disease requiring hemodialysis. Accordingly, no dosage recommendation has been given for patients with severe renal impairment or end-stage renal disease requiring dialysis.
  • Hepatic Impairment: For patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C), no dosage adjustment for sofosbuvir plus velpatasvir is recommended. For patients with decompensated cirrhosis who are receiving sofosbuvir-velpatasvir and ribavirin, clinical and laboratory monitoring is recommended.

Store:

Sofosbuvir With Velpatasvir room temperature away from moisture and heat.

Warning

Sofosbuvir plus Velpatasvir is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofosbuvir Side effects:

The most common Side effects (≥10%, all grades) with Sofosbuvir plus Velpatasvir were headache and fatigue; and when used with Ribavirin in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Precaution:

  • Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir plus Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Sofosbuvir plus Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.